Journal: bioRxiv
Article Title: Probing immune signatures of conjugated pattern recognition receptor ligands identifies chimeras with adjuvant and antitumor activity
doi: 10.1101/2025.04.07.647694
Figure Lengend Snippet: Treatment of BDMCs with conjugates promotes their antigen presenting activity and enhances antigen-specific activation and proliferation of CD4 + and CD8 + T cells. BMDCs from C57BL/6 mice were treated for 18 h with conjugates (1 μM), LPS (1 μg/mL), or vehicle (0.1% DMSO) in the presence of OVA (50 μg/mL). CFSE-labeled OVA-specific CD4+ or CD8+ T cells (isolated from OT-II or OT-I mouse splenocytes, respectively) were added to the treated and washed BMDCs and cocultured for 72 h. (A) Representative dot plots show CD25 expression and CFSE dilution in live Thy1.2+/CD4+ (OTII) and Thy1.2+/CD8+ (OTI) T cells. (B) Pooled data from (A), expressed as proliferation indexes. (C) Cytokine concentrations in BMDC/T-cell coculture supernatants following 72 h coincubation. Data are mean ± SEM of duplicates of two independent experiments. *, p < 0.05, **, p <0.01, ***, p <0.001, ****, p <0.0001 versus vehicle-treated control. Statistical significance was determined using one-way ANOVA with post-hoc Dunnett’s test comparing conjugates versus OVA.
Article Snippet: Then, 5 × 10 4 T cells were cultured in duplicate with 1 × 10 4 BMDCs/well (pretreated with compounds [1 μM] or LPS [1 μg/mL] and 50 μg/mL ovalbumin (OVA) soluble protein [Invivogen, San Diego, CA] for 18 h, and then washed).
Techniques: Activity Assay, Activation Assay, Labeling, Isolation, Expressing, Control
